Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 279

1.

Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity.

Alspach E, Lussier DM, Schreiber RD.

Cold Spring Harb Perspect Biol. 2018 Apr 16. pii: a028480. doi: 10.1101/cshperspect.a028480. [Epub ahead of print]

PMID:
29661791
2.

Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma.

Zolkind P, Przybylski D, Marjanovic N, Nguyen L, Lin T, Johanns T, Alexandrov A, Zhou L, Allen CT, Miceli AP, Schreiber RD, Artyomov M, Dunn GP, Uppaluri R.

Oncotarget. 2017 Dec 28;9(3):4109-4119. doi: 10.18632/oncotarget.23751. eCollection 2018 Jan 9.

3.

Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells.

Fehlings M, Simoni Y, Penny HL, Becht E, Loh CY, Gubin MM, Ward JP, Wong SC, Schreiber RD, Newell EW.

Nat Commun. 2017 Sep 15;8(1):562. doi: 10.1038/s41467-017-00627-z.

4.

Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during a mucosal viral infection.

Lee AJ, Chen B, Chew MV, Barra NG, Shenouda MM, Nham T, van Rooijen N, Jordana M, Mossman KL, Schreiber RD, Mack M, Ashkar AA.

J Exp Med. 2017 Apr 3;214(4):1153-1167. doi: 10.1084/jem.20160880. Epub 2017 Mar 6.

5.

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.

Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hundal J, Selby MJ, Graziano RF, Mardis ER, Korman AJ, Schreiber RD.

Cancer Immunol Res. 2017 Feb;5(2):106-117. doi: 10.1158/2326-6066.CIR-16-0391. Epub 2017 Jan 10.

6.

Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach.

Johanns TM, Ward JP, Miller CA, Wilson C, Kobayashi DK, Bender D, Fu Y, Alexandrov A, Mardis ER, Artyomov MN, Schreiber RD, Dunn GP.

Cancer Immunol Res. 2016 Dec;4(12):1007-1015. Epub 2016 Oct 31.

7.

Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity.

Putz EM, Majoros A, Gotthardt D, Prchal-Murphy M, Zebedin-Brandl EM, Fux DA, Schlattl A, Schreiber RD, Carotta S, Müller M, Gerner C, Decker T, Sexl V.

Oncoimmunology. 2016 May 19;5(9):e1186314. eCollection 2016.

8.

Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas.

Griffith OL, Chan SR, Griffith M, Krysiak K, Skidmore ZL, Hundal J, Allen JA, Arthur CD, Runci D, Bugatti M, Miceli AP, Schmidt H, Trani L, Kanchi KL, Miller CA, Larson DE, Fulton RS, Vermi W, Wilson RK, Schreiber RD, Mardis ER.

Cell Rep. 2016 Sep 27;17(1):249-260. doi: 10.1016/j.celrep.2016.08.076.

9.

Novel ERα positive breast cancer model with estrogen independent growth in the bone microenvironment.

Capietto AH, Chan SR, Ricci B, Allen JA, Su X, Novack DV, Schreiber RD, Faccio R.

Oncotarget. 2016 Aug 2;7(31):49751-49764. doi: 10.18632/oncotarget.10443.

10.

NKG2D-NKG2D Ligand Interaction Inhibits the Outgrowth of Naturally Arising Low-Grade B Cell Lymphoma In Vivo.

Raju S, Kretzmer LZ, Koues OI, Payton JE, Oltz EM, Cashen A, Polic B, Schreiber RD, Shaw AS, Markiewicz MA.

J Immunol. 2016 Jun 1;196(11):4805-13. doi: 10.4049/jimmunol.1501982. Epub 2016 May 2.

11.

Preface.

Schreiber RD.

Adv Immunol. 2016;130:xi-xiii. doi: 10.1016/S0065-2776(16)30010-4. No abstract available.

PMID:
26923005
12.

The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.

Ward JP, Gubin MM, Schreiber RD.

Adv Immunol. 2016;130:25-74. doi: 10.1016/bs.ai.2016.01.001. Epub 2016 Feb 10. Review.

PMID:
26922999
13.

Fresh Beginnings.

Greenberg PD, Schreiber RD, Miller LJ.

Cancer Immunol Res. 2016 Jan;4(1):1-2. doi: 10.1158/2326-6066.CIR-15-0304. No abstract available.

14.

Dual Requirement of Cytokine and Activation Receptor Triggering for Cytotoxic Control of Murine Cytomegalovirus by NK Cells.

Parikh BA, Piersma SJ, Pak-Wittel MA, Yang L, Schreiber RD, Yokoyama WM.

PLoS Pathog. 2015 Dec 31;11(12):e1005323. doi: 10.1371/journal.ppat.1005323. eCollection 2015 Dec.

15.

CANCER. The odds of immunotherapy success.

Gubin MM, Schreiber RD.

Science. 2015 Oct 9;350(6257):158-9. doi: 10.1126/science.aad4140. No abstract available.

PMID:
26450194
16.

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.

Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, Tonc E, Schreiber RD, Pearce EJ, Pearce EL.

Cell. 2015 Sep 10;162(6):1229-41. doi: 10.1016/j.cell.2015.08.016. Epub 2015 Aug 27.

17.

Tumor neoantigens: building a framework for personalized cancer immunotherapy.

Gubin MM, Artyomov MN, Mardis ER, Schreiber RD.

J Clin Invest. 2015 Sep;125(9):3413-21. doi: 10.1172/JCI80008. Epub 2015 Aug 10. Review.

18.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

19.

Abnormal Mammary Development in 129:STAT1-Null Mice is Stroma-Dependent.

Chen JQ, Mori H, Cardiff RD, Trott JF, Hovey RC, Hubbard NE, Engelberg JA, Tepper CG, Willis BJ, Khan IH, Ravindran RK, Chan SR, Schreiber RD, Borowsky AD.

PLoS One. 2015 Jun 15;10(6):e0129895. doi: 10.1371/journal.pone.0129895. eCollection 2015.

20.

Selective Blockade of Interferon-α and -β Reveals Their Non-Redundant Functions in a Mouse Model of West Nile Virus Infection.

Sheehan KC, Lazear HM, Diamond MS, Schreiber RD.

PLoS One. 2015 May 26;10(5):e0128636. doi: 10.1371/journal.pone.0128636. eCollection 2015.

21.

Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection.

Ng CT, Sullivan BM, Teijaro JR, Lee AM, Welch M, Rice S, Sheehan KC, Schreiber RD, Oldstone MB.

Cell Host Microbe. 2015 May 13;17(5):653-61. doi: 10.1016/j.chom.2015.04.005.

22.

Neoantigens in cancer immunotherapy.

Schumacher TN, Schreiber RD.

Science. 2015 Apr 3;348(6230):69-74. doi: 10.1126/science.aaa4971. Review.

PMID:
25838375
23.

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD.

Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988.

24.

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tüting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Préville X, Uzè G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, André F, Kroemer G, Zitvogel L.

Nat Med. 2014 Nov;20(11):1301-9. doi: 10.1038/nm.3708. Epub 2014 Oct 26.

PMID:
25344738
25.

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.

Mittal D, Gubin MM, Schreiber RD, Smyth MJ.

Curr Opin Immunol. 2014 Apr;27:16-25. doi: 10.1016/j.coi.2014.01.004. Epub 2014 Feb 14. Review.

26.

Loss of DAP12 and FcRγ drives exaggerated IL-12 production and CD8(+) T cell response by CCR2(+) Mo-DCs.

Gmyrek GB, Akilesh HM, Graham DB, Fuchs A, Yang L, Miller MJ, Sandoval GJ, Sheehan KC, Schreiber RD, Diamond MS, Swat W.

PLoS One. 2013 Oct 14;8(10):e76145. doi: 10.1371/journal.pone.0076145. eCollection 2013.

27.

Identifying the initiating events of anti-Listeria responses using mice with conditional loss of IFN-γ receptor subunit 1 (IFNGR1).

Lee SH, Carrero JA, Uppaluri R, White JM, Archambault JM, Lai KS, Chan SR, Sheehan KC, Unanue ER, Schreiber RD.

J Immunol. 2013 Oct 15;191(8):4223-34. doi: 10.4049/jimmunol.1300910. Epub 2013 Sep 18.

28.

Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα(+) tumorigenesis.

Chan SR, Rickert CG, Vermi W, Sheehan KC, Arthur C, Allen JA, White JM, Archambault J, Lonardi S, McDevitt TM, Bhattacharya D, Lorenzi MV, Allred DC, Schreiber RD.

Cell Death Differ. 2014 Feb;21(2):234-46. doi: 10.1038/cdd.2013.116. Epub 2013 Sep 13.

29.

Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy.

Vesely MD, Schreiber RD.

Ann N Y Acad Sci. 2013 May;1284:1-5. doi: 10.1111/nyas.12105.

30.

Persistent LCMV infection is controlled by blockade of type I interferon signaling.

Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, Schreiber RD, de la Torre JC, Oldstone MB.

Science. 2013 Apr 12;340(6129):207-11. doi: 10.1126/science.1235214.

31.

Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed mice.

Baccala R, Gonzalez-Quintial R, Schreiber RD, Lawson BR, Kono DH, Theofilopoulos AN.

J Immunol. 2012 Dec 15;189(12):5976-84. doi: 10.4049/jimmunol.1201477. Epub 2012 Nov 21.

32.

Programmable nanoparticle functionalization for in vivo targeting.

Pan H, Myerson JW, Hu L, Marsh JN, Hou K, Scott MJ, Allen JS, Hu G, San Roman S, Lanza GM, Schreiber RD, Schlesinger PH, Wickline SA.

FASEB J. 2013 Jan;27(1):255-64. doi: 10.1096/fj.12-218081. Epub 2012 Oct 9.

33.

Critical role for interferon regulatory factor 3 (IRF-3) and IRF-7 in type I interferon-mediated control of murine norovirus replication.

Thackray LB, Duan E, Lazear HM, Kambal A, Schreiber RD, Diamond MS, Virgin HW.

J Virol. 2012 Dec;86(24):13515-23. doi: 10.1128/JVI.01824-12. Epub 2012 Oct 3.

34.

Compensatory dendritic cell development mediated by BATF-IRF interactions.

Tussiwand R, Lee WL, Murphy TL, Mashayekhi M, KC W, Albring JC, Satpathy AT, Rotondo JA, Edelson BT, Kretzer NM, Wu X, Weiss LA, Glasmacher E, Li P, Liao W, Behnke M, Lam SS, Aurthur CT, Leonard WJ, Singh H, Stallings CL, Sibley LD, Schreiber RD, Murphy KM.

Nature. 2012 Oct 25;490(7421):502-7. doi: 10.1038/nature11531. Epub 2012 Sep 19.

35.

Cancer immunoediting by the innate immune system in the absence of adaptive immunity.

O'Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C, White JM, Uppaluri R, Andrews DM, Ngiow SF, Teng MW, Smyth MJ, Schreiber RD, Bui JD.

J Exp Med. 2012 Sep 24;209(10):1869-82. Epub 2012 Aug 27.

36.

Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state.

Teng MW, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD, Smyth MJ.

Cancer Res. 2012 Aug 15;72(16):3987-96. doi: 10.1158/0008-5472.CAN-12-1337. Epub 2012 Aug 6.

37.

Strain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancer.

Kreisel D, Gelman AE, Higashikubo R, Lin X, Vikis HG, White JM, Toth KA, Deshpande C, Carreno BM, You M, Taffner SM, Yokoyama WM, Bui JD, Schreiber RD, Krupnick AS.

Cancer Res. 2012 Sep 1;72(17):4311-7. Epub 2012 Jun 29.

38.

A dual function of NKG2D ligands in NK-cell activation.

Cheney EE, Wise EL, Bui JD, Schreiber RD, Carayannopoulos LN, Spitzer D, Zafirova B, Polic B, Shaw AS, Markiewicz MA.

Eur J Immunol. 2012 Sep;42(9):2452-8. doi: 10.1002/eji.201141849. Epub 2012 Jul 27.

39.

Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection.

Wang Y, Swiecki M, Cella M, Alber G, Schreiber RD, Gilfillan S, Colonna M.

Cell Host Microbe. 2012 Jun 14;11(6):631-42. doi: 10.1016/j.chom.2012.05.003.

40.

Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.

Fowler AM, Chan SR, Sharp TL, Fettig NM, Zhou D, Dence CS, Carlson KE, Jeyakumar M, Katzenellenbogen JA, Schreiber RD, Welch MJ.

J Nucl Med. 2012 Jul;53(7):1119-26. doi: 10.2967/jnumed.112.103465. Epub 2012 Jun 5.

41.

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.

Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD.

Nature. 2012 Feb 8;482(7385):400-4. doi: 10.1038/nature10755.

42.

STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.

Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, Lonardi S, Arthur C, Young LJ, Levy DE, Welch MJ, Cardiff RD, Schreiber RD.

Breast Cancer Res. 2012 Jan 20;14(1):R16.

43.

A temporal role of type I interferon signaling in CD8+ T cell maturation during acute West Nile virus infection.

Pinto AK, Daffis S, Brien JD, Gainey MD, Yokoyama WM, Sheehan KC, Murphy KM, Schreiber RD, Diamond MS.

PLoS Pathog. 2011 Dec;7(12):e1002407. doi: 10.1371/journal.ppat.1002407. Epub 2011 Dec 1.

44.

Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo.

Swiecki M, Wang Y, Vermi W, Gilfillan S, Schreiber RD, Colonna M.

J Exp Med. 2011 Nov 21;208(12):2367-74. doi: 10.1084/jem.20110654. Epub 2011 Nov 14.

45.

Type I interferon is selectively required by dendritic cells for immune rejection of tumors.

Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD.

J Exp Med. 2011 Sep 26;208(10):1989-2003. doi: 10.1084/jem.20101158. Epub 2011 Sep 19.

46.

Cancer immunoediting of the NK group 2D ligand H60a.

O'Sullivan T, Dunn GP, Lacoursiere DY, Schreiber RD, Bui JD.

J Immunol. 2011 Oct 1;187(7):3538-45. doi: 10.4049/jimmunol.1100413. Epub 2011 Aug 29.

47.

CD8α(+) dendritic cells are an obligate cellular entry point for productive infection by Listeria monocytogenes.

Edelson BT, Bradstreet TR, Hildner K, Carrero JA, Frederick KE, KC W, Belizaire R, Aoshi T, Schreiber RD, Miller MJ, Murphy TL, Unanue ER, Murphy KM.

Immunity. 2011 Aug 26;35(2):236-48. doi: 10.1016/j.immuni.2011.06.012.

48.

CXCR3 enhances a T-cell-dependent epidermal proliferative response and promotes skin tumorigenesis.

Winkler AE, Brotman JJ, Pittman ME, Judd NP, Lewis JS Jr, Schreiber RD, Uppaluri R.

Cancer Res. 2011 Sep 1;71(17):5707-16. doi: 10.1158/0008-5472.CAN-11-0907. Epub 2011 Jul 6.

49.

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Schreiber RD, Old LJ, Smyth MJ.

Science. 2011 Mar 25;331(6024):1565-70. doi: 10.1126/science.1203486. Review.

PMID:
21436444
50.

Natural innate and adaptive immunity to cancer.

Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ.

Annu Rev Immunol. 2011;29:235-71. doi: 10.1146/annurev-immunol-031210-101324. Review.

PMID:
21219185

Supplemental Content

Loading ...
Support Center